Roche secures rights to potential COVID-19 drug

22-10-2020

Rory O'Neill

Roche secures rights to potential COVID-19 drug

Sundry Photography / Shutterstock.com

Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.


Roche, Area Pharmaceuticals, COVID-19, antiviral, AT-527, biotechnology, pandemic, RNA

LSIPR